Velpanat (Sofosbuvir/Velpatasvir) 400 mg / 100 mg
Velpanat is a premium pan-genotypic fixed-dose combination for Hepatitis C treatment. Active ingredients: Sofosbuvir (400 mg) + Velpatasvir (100 mg).
Manufacturer: Natco Pharma (India). Recognized as the highest quality generic equivalent of Epclusa.
The "One Pill for All" Solution:
Velpanat simplifies treatment by covering ALL genotypes (1-6). Manufactured by Natco, a global leader in hepatitis care, it guarantees high purity and efficacy. It is the preferred regimen for the difficult-to-treat Genotype 3.
✅ Efficacy: Cure rates exceeding 98-99% with a standard 12-week course.
Indicated for the treatment of chronic HCV infection in adults:
- Pan-genotypic: Effective against Genotypes 1, 2, 3, 4, 5, and 6.
- Liver Status: For patients without cirrhosis or with compensated cirrhosis.
- Decompensated Cirrhosis: Used in combination with Ribavirin.
Standard Dosage: One tablet daily for 12 weeks.
⚠️ IMPORTANT: ACID REDUCING AGENTS
Velpatasvir requires gastric acid for absorption. If you use PPIs (like Omeprazole):
- Take Velpanat with food.
- Take Omeprazole (max 20 mg) 4 hours AFTER Velpanat.
- Separate antacids (aluminum/magnesium) by at least 4 hours.
🚫 DANGER: AMIODARONE.
Do not take with Amiodarone (antiarrhythmic). This combination causes severe bradycardia and heart block.
Other Contraindications:
- Pregnancy and breastfeeding.
- Co-administration with strong P-gp inducers (Rifampin, St. John's Wort) as they decrease therapeutic levels.
Side effects are typically minimal:
- Headache, Fatigue, Nausea.
- HBV Warning: Hepatitis B reactivation. All patients must be screened for Hepatitis B before starting treatment to prevent potentially fatal liver failure due to HBV flare-up.
What Customers Say
No reviews yet
Your review can be the first!